Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

Table 3 Median overall survival and progression-free survival of unresectable hepatocellular carcinoma patients who received atezolizumab plus bevacizumab therapy stratified by liver function, tumor size, and tumor stage

Variables	No. of events/No. of patients	Median OS (95%CI), mo	P value	No. of events/No. of patients	Median OS (95%CI), mo	P value
A. Entire cohort, n = 83
CTP class			< 0.001			NE
CTP A	25/65	17 (-)		34/65	9.0 (5.1-12.9)
CTP B	14/18	2.0 (1.1-2.9)		3/18	NE
Tumor size in cm			0.790			0.130
≤ 5.0	21/41	12.0 (4.8-19.2)		21/41	7.0 (2.8-11.2)
> 5.0	18/42	NE		16/42	16.0 (6.5-25.5)
B. BCLC C group, n = 61	27/61	14.0 (-)		28/61	10.0 (0.5-19.5)
CTP class			< 0.001			0.810
CTP A	18/49	NE		26/49	10.0 (0.3-19.7)
CTP B	9/12	1.0 (0.1-2.5)		2/12	NE
Tumor size in cm			0.850			0.060
≤ 5.0	13/26	12.0 (3.4-20.6)		15/26	6.0 (2.5-9.5)
> 5.0	14/35	NE		13/35	24.0 (9.4-38.6)
With PV invasion, n = 30			0.140			0.030
No	12/31	NE		20/31	6.0 (3.2-8.8)
Yes	15/30	13.0 (2.0-24.0)		8/30	24.0 (-)
With EHM metastasis, n = 40			0.540			0.170
No	10/21	13.0 (0.1-27.3)		7/21	24 (-)
Yes	17/40	NE		21/40	6.0 (1.1-10.9)
C. BCLC B group, n = 22	12/22	11.0 (2.7-19.3)		9/22	8.0 (1.3-14.7)
CTP class			0.020			0.660
CTP A	7/16	11.0 (5.6-16.4)		8/16	8.0 (1.5-14.5)
CTP B	5/6	2.0 (0.8-3.2)		1/6	5.0 (-)
Tumor size in cm			0.490			0.140
≤ 5.0	8/15	11.0 (0.1-24.1)		6/15	9.0 (6.9-11.1)
> 5.0	4/7	7.0 (0.1-17.3)		3/7	5.0 (-)

CI: Confidence interval; BCLC: Barcelona Clinic Liver Cancer; CTP: Child-Turcotte-Pugh; EHM: Extrahepatic metastasis; NE: Not estimated; OS: Overall survival; PFS: Progression-free survival; PV: Pulmonary vein.